Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REC625
- Development stage
- Preclinical
- Lead developer
- Recbio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
REC625 is a novel adjuvanted recombinant respiratory syncytial virus (RSV) vaccine candidate. It incorporates the proprietary adjuvant BFA01, which is designed to enhance immune response. The vaccine is being developed for the prevention of RSV infection, a significant cause of respiratory illness in infants, young children, and older adults. REC625 is under development by Jiangsu Recbio Technology[3].
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on REC625.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REC625.